Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Achondroplasia, the most prevalent skeletal dysplasia, stems from a functional mutation in the fibroblast growth factor receptor 3 gene, leading to growth impairment. This condition presents multifaceted medical, functional and psychosocial challenges throughout childhood, adolescence and adulthood. Current management strategies aim to minimise medical complications, optimise functional capabilities and provide comprehensive supportive care. Vosoritide (trade name: VOXZOGO, BioMarin Pharmaceuticals) is the first disease-modifying pharmaceutical treatment approved for the management of patients with achondroplasia and became available in Australia in May 2023.
Methods: Standardised clinical guidelines for its optimal use are not yet widely available. To address this gap, a multidisciplinary Australian Vosoritide Working Group, comprising 12 experts with experience in achondroplasia management from across Australia, developed recommendations to guide the use of vosoritide in clinical practice.
Results: The recommendations, which are expert opinions of the Australian Vosoritide Working Group, aim to (i) standardise the use of vosoritide across Australia, (ii) support the safe clinical rollout of vosoritide and (iii) support universal access.
Conclusions: These recommendations have been developed for healthcare professionals and institutions that are engaged in using vosoritide in the management of achondroplasia and will be revised using a formal framework for clinical guideline development once more evidence is available.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11274906 | PMC |
| http://dx.doi.org/10.3390/children11070789 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence.
Cureus
July 2025
Pediatrics, Midwestern University Arizona College of Osteopathic Medicine, Glendale, USA.
Achondroplasia is the most common genetic skeletal dysplasia, caused by activating mutations in the FGFR3 gene that impair endochondral ossification and result in disproportionate short stature. Vosoritide (VOXZOGO®), a C-type natriuretic peptide analog, is the first targeted therapy approved for achondroplasia and acts by antagonizing FGFR3 signaling to promote bone growth. This review evaluates current clinical evidence on the efficacy, safety, and long-term potential of vosoritide in children with achondroplasia.
View Article and Find Full Text PDFPerception and Attitude towards Fertility and Fertility Preservation Options in Parents of Children with Turner Syndrome: A Qualitative Survey Study.
J Pediatr Adolesc Gynecol
August 2025
Division of Endocrinology, Children's National Hospital, Washington, DC, US; The George Washington University School of Medicine, Washington, DC, US. Electronic address:
Study Objective: Turner Syndrome (TS) is a genetic condition often characterized by ovarian insufficiency and infertility. Fertility preservation discussions are recommended early in care, but few studies have explored parental perspectives. Our objective was to assess the knowledge, perceptions, and attitudes regarding fertility and fertility preservation among parents of young children with TS.
View Article and Find Full Text PDFIntegrating vosoritide therapy with limb surgery in paediatric patients with achondroplasia: real-life experiences.
Orphanet J Rare Dis
July 2025
Center for Rare Diseases, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Background: Achondroplasia is the most common form of disproportionate short stature and can lead to serious medical complications, including foramen magnum and spinal stenosis. Until 2021, there were no precision treatments available, and in some countries, elective surgery was considered a standard approach to increase height, improve body proportions, enhance functionality, and correct deformities in a selected group of patients. Recently, C-type natriuretic peptide (CNP) has been explored as a potential treatment, aiming to counteract the molecular activity driven by FGFR3.
View Article and Find Full Text PDFSleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review.
Arch Dis Child
July 2025
Molecular Therapies, Murdoch Children's Research Institute, Parkville, Victoria, Australia
Objectives: Sleep-disordered breathing is a key childhood complication in children with achondroplasia. This retrospective study aimed to document the prevalence of sleep-disordered breathing in children with achondroplasia assessed by polysomnography.
Design: The prevalence of sleep-disordered breathing assessed by polysomnography among children aged 0-18 years with achondroplasia from 2013 to 2024 at The Royal Children's Hospital, Australia, was retrospectively reviewed.
Genetics of short stature.
Curr Opin Pediatr
August 2025
Division of Endocrinology and Center for Genetic Medicine Research, Children's National Hospital.
Purpose Of Review: This review highlights recent genetic discoveries and therapeutic advancements in evaluating and managing children with short stature. With an increasing diagnostic yield from genetic testing and the emergence of genotype-specific treatments, a comprehensive update is necessary for timely application in clinical practice.
Recent Findings: New pathogenic variants have been identified in genes, including FBN1, IHH, NPR2, ACAN, FGFR3, COMP, MATN3, EXT2, and LZTR1, associated with syndromic and nonsyndromic short stature.